FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—March 24, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it will be cross-promoting selected partners who also clearly promote affordable public health.
Said GenoMed’s CEO, David Moskowitz MD, “We are proud to announce that our first partner in this program is the inventor of the portable electronic health record, Safe Guard Medi-Systems Corporation.”
The purpose of GenoMed’s program is to create a network of reliable providers of affordable, useful products for patients.
Dr. Moskowitz continued by saying, “Our mission is to minimize the impact of disease. There’s no question that having your medical chart on you can make a huge difference in your care, especially after an accident or during a natural disaster. One of the big lessons of Hurricane Katrina is that a person’s health record has to be portable. Safe Guard Medi-Systems’ chip makes so much sense.”
Dr. Moskowitz ended by saying, “We’re happy to make our customers aware of SGMS Corp., and, I’m happy to say, SGMS Corp. is happy to tell their customers about us. SGMS is selling its medi-chips in drugstores in the US and abroad. We look forward to additional cross-promotional arrangements with other companies.”
About SGMS, Corp. (http://www.sgmscorp.com) SGMS, Corp. makes an affordable, comprehensive and portable electronic medical record available to every American. It provides all medical personnel with instant access to life-saving information to ensure appropriate and timely patient care.
About GenoMed (GenoMed”>http://www.genomed.com)
GenoMed is a Next Generation Disease Management company that hunts for disease genes in order to conquer disease. In 2002, GenoMed published how to prevent 90% of kidney failure, and how to slow down emphysema (COPD). GenoMed’s clinical “recipes” are the subject of pending patents in the US. Two patents have been awarded: one for treating acute kidney failure without dialysis, and a second for speeding up lung maturation in premature infants. In 2004, GenoMed took on cancer, and hopes to have FDA approval for its cancer Healthchip(r) soon.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.